Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 11/20 | 0.51 |
| ▸ | GRK5 | P34947 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5366834 | 0.85 | GSK3B (0.52) | PAK4GSK3BPDGFRBKDR | |
| SCHEMBL14519109 | 0.82 | TLK2 (0.57) | PAK4MEN1KMT2APDGFRBKDR | |
| SCHEMBL5367344 | 0.82 | GRK5 (0.51) | PAK4GRK5ALDH1A1MEN1GAA | |
| SCHEMBL5368286 | 0.81 | PAK4 (0.69) | PAK4GRK5MEN1TSHRKMT2A | |
| SCHEMBL25313929 | 0.80 | GRK5 (0.63) | GRK5PDGFRBKDR | |
| SCHEMBL25313935 | 0.80 | GRK5 (0.63) | GRK5PDGFRBKDR | |
| SCHEMBL5368073 | 0.79 | PDPK1 (0.61) | PAK4GSK3B | |
| SCHEMBL5368518 | 0.79 | PAK4 (0.75) | PAK4 | |
| SCHEMBL5365829 | 0.78 | PDPK1 (0.48) | PAK4GSK3BPDGFRBKDR | |
| SCHEMBL6666023 | 0.78 | ALDH1A1 (0.51) | PAK4GRK5ALDH1A1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
| EP-1247803-A2 | Indolinone compounds suitable for modulation of protein kinases | Sugen, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | PAK4 682/4885GRK5 205/4885ALDH1A1 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.